This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - April 07, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol Myers/Acceleron's Reblozyl Label Expansion Gets FDA Nod
by Zacks Equity Research
Bristol Myers (BMY) and Acceleron received FDA nod for the label expansion of Reblozyl for MDS patients who require RBC transfusions, failing an erythropoiesis stimulating agent.
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates
by Kinjel Shah
J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
Coronavirus-Led Volatility Rises: 5 High Earnings Yield Picks
by Zacks Equity Research
Dodge the COVID-19 pandemic by investing in these high earnings yield stocks.
Fate Therapeutics Surges on Immunotherapy Deal With J&J
by Zacks Equity Research
Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company.
Top Ranked Income Stocks to Buy for April 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 2nd.
Bristol-Myers Squibb (BMY) Stock Moves -1.58%: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $54.86, moving -1.58% from the previous trading session.
Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA
by Zacks Equity Research
Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.
Powerful Proof Anyone Can Invest for an Early Retirement - April 01, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
BMY or AZN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - March 31, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Top Ranked Income Stocks to Buy for March 31st
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 31st.
Top Research Reports for American Tower, Equinix & Deere
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including American Tower (AMT), Equinix (EQIX) and Deere (DE).
Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View
by Zacks Equity Research
Vertex (VRTX) announces plan to halt enrollment and delay study initiation amid coronavirus pandemic. However, it does not expect any supply chain disruption and maintains its business outlook for 2020.
AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic
by Zacks Equity Research
AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.
Are You Looking for a High-Growth Dividend Stock? Bristol-Myers Squibb (BMY) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
AstraZeneca's Imfinzi Gets FDA Nod for SCLC Label Expansion
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi gets FDA approval as first-line treatment for extensive-stage small cell lung cancer patients. A phase III study on Farxiga in CKD patients meets endpoint earlier than expected.
Sanofi Begins Kevzara Study for Severe Coronavirus Infection
by Zacks Equity Research
Sanofi (SNY) begins treatment in a second phase II/III study evaluating its rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19 outside the United States.
Signs That Your Trading Will Ruin Your Retirement - March 30, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia
by Zacks Equity Research
The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.
Company News for Mar 27, 2020
by Zacks Equity Research
Companies in the news are: BMY, WORK, SIG, FDS
Pharma, Biotech Players Step Up Efforts Against Coronavirus
by Indrajit Bandyopadhyay
Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.
Infinity's IPI-549 Gets Fast Track Tag for Urothelial Cancer
by Zacks Equity Research
The FDA bestows a Fast Track designation on Infinity's (INFI) IPI-549 in combination with Opdivo for treating advanced urothelial cancer. Stock rise.
Zacks.com featured highlights include: Bristol-Myers Squibb, AmerisourceBergen, Leidos, Xcel Energy and Caseys General Stores
by Zacks Equity Research
Zacks.com featured highlights include: Bristol-Myers Squibb, AmerisourceBergen, Leidos, Xcel Energy and Caseys General Stores
5 Top Picks to Tap the Dow and S&P 500's Back-to-Back Rally
by Nalak Das
Stocks have fallen significantly in a short period of time and several of them offer lucrative buying opportunity at this stage.